A pharmaceutical company called AlzeCure Pharma has shared exciting new findings about a drug called NeuroRestore ACD856, which is being developed to treat Alzheimer’s disease. These results were presented at the AD/PD 2026 international conference, and the full details can now be found on the company’s website. The new research supports the drug’s ability to work in the body and its potential to help people with memory problems and depression.
Cristina Parrado-Fernández, a senior scientist at AlzeCure, explained that the drug works by affecting two important proteins in the brain called NGF and BDNF. These proteins help nerve cells communicate and stay healthy. When this communication improves, it can lead to better memory and even reduce symptoms of depression.
The studies showed that ACD856 activates certain receptors in the brain in a dose-dependent way, meaning that higher doses produce stronger effects. These effects were also observed in living organisms, where the drug led to noticeable antidepressant effects. This is especially important because many people with Alzheimer’s also struggle with depression, and depression itself is a major global health issue.
AlzeCure’s NeuroRestore platform is designed to enhance communication between nerve cells and improve cognitive functions like learning and memory. Earlier research has also suggested that this type of drug may protect nerve cells and reduce inflammation in the brain.
ACD856 is considered a first-of-its-kind drug, and it is now preparing for phase 2 clinical trials. Recently, it received significant funding from the European Innovation Council to support further development.
Martin Jönsson, the CEO of AlzeCure, said: ‘The positive results we’ve seen so far with ACD856, along with these new preclinical findings that confirm its mechanism and show strong antidepressant effects, make it a very promising drug candidate. This not only increases our opportunities in business development but also gives hope for better treatments for Alzheimer’s and depression in the future.’